Logo

Detroit R&D Secures $1.2 Million in SBIR Grants

Nov 10, 2003

NEW YORK, Nov. 10 (GenomeWeb News) - Detroit R&D said today that it has received $1.2 million in new phase I and phase II SBIR grants, which will support the company's continued genomic and proteomic research into xenobiotic and toxic substances metabolism.

 

The first phase I grant will provide $100,000 to support of the development of antibody chips to screen drug-metabolizing enzymes, said Detroit R&D. The second phase I grant is for $400,000, and will be used to find markers for fetal alcohol syndrome.

 

Detroit R&D said that the phase II grant, worth $750,000, was awarded to help in the development of frog embryo DNA microarrays as a tool for toxicogenomic studies.

 

 

Breaking News
The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.